Guoxin Yongfeng Fund, Haifutong Fund, Nord Fund, Blackrock Fund, Galaxy Fund, Wanjia Fund, Ivy assets, Huihua Financial Management, Yuxiu Capital, Haitong Capital Management, Oriental Jiafu and Shenwan Capital Management will investigate and study our company on September 23, 2021, according to a notice issued by Jianyu Information (605186) on October 8, 2021.

The main contents of this survey are as follows:
1. What is the overall performance of the company in the first half of 2021? Answer: in the first half of 2021, the management of the company strictly followed the business plan formulated by the board of directors at the beginning of the year, seized the market opportunities, continued to improve operation and management, and successfully completed the various phased goals and tasks set at the beginning of the year. In the first half of 2021, the company achieved operating income of 151.6654 million yuan, an increase of 20.74% over the same period last year, mainly due to the expansion of sales. The net profit attributable to shareholders of listed companies was 51.7625 million yuan, an increase of 21.40% over the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurrent profits and losses was 46.4118 million yuan, an increase of 24.62% over the same period last year. The growth in performance in the first half of 2021 was mainly due to the increase in operating profits.
2. How is the progress of the company's layout of the pharmaceutical retail market? Answer: in the first half of 2021, the company reached a strategic cooperation with Gaoji Medical. Both sides are optimistic about the development of Wisdom Future drugstores in the new retail field, and plan to jointly explore the innovative model of Wisdom drugstores and build future pharmacies. The two sides have taken the lead in piloting some pharmacies under Gaoji Medical through the use of the company's smart retail equipment in Beijing and Shanghai. With the steady progress of the strategic cooperation with Gaoji Medical to build the "Future Pharmacy", the company and Yifeng Pharmacy also reached the strategic cooperation of "Digital Wisdom Pharmacy" in the second half of 2021, and the two sides will take the lead in carrying out pilot projects in Shanghai.
3. In addition to the original main business section, is there a new business section? Answer: following the trend of the industry, the company opened two new business sectors, namely, hospital box logistics and traditional Chinese medicine dispensing automation, in the first half of 2021. Strategic cooperation was reached with Beijing 3D Hairong Technology Co., Ltd., which is the most influential enterprise in the two sectors, and Beijing Helikangyuan Medical Technology Co., Ltd. Through the in-depth cooperation of key projects in the field of pharmacy automation, we can strengthen the complementary advantages and omni-directional support of both sides in their respective business fields, which will help the company to quickly enrich its product line, improve its product system and enhance its comprehensive profitability.
4. The company also seems to be in line with the characteristics of specialized and special new enterprises advocated by the country now. does it belong to specialized and special new enterprises? Answer: "specialized and special new" enterprises focus on market segmentation, focus on the main business, strong innovation ability, high market share, core competitiveness, and are the vanguard of high-quality development and an important birthplace of innovation. The company has always attached great importance to the development of "specialization and innovation". In 2019, the company was listed in 2019 by the Shanghai Municipal Coordination Office for promoting the Development of small and medium-sized Enterprises. At the same time, the company's wholly-owned subsidiary Shanghai Guotao Information Technology Co., Ltd. was listed by the Ministry of Industry and Information Technology as the third batch of "Little Giant" enterprises in 2021.
5. What are the main advantage markets of the company? Answer: at present, the company's main advantage market is in the economically developed coastal areas, especially the third-tier hospital customer base in first-and second-tier cities. In the first half of 2021, the company will increase its efforts to expand the market and rationally distribute its business to the vast central and western regions and low-level medical service institutions. In the first half of 2021, the company bought a 15% stake in Brocade Guoxin in the form of a capital increase. Bokoguoxin's business positioning is complementary to the company's business. If there is a direct correlation between its product medical consumables SPD management system and the company's product intelligent consumables management cabinet, through cooperation between the two sides, it can provide medical service institutions with a more complete solution and jointly create an ecological closed loop in the hospital, which has important strategic synergy significance for the company to open up and distribute the B-end sinking market. At the same time, Boko Guoxin has many years of market channels and customer resources in Hunan, Hubei, Chongqing and other regions. In the first half of 2021, the company has established business cooperation with Brocade Guoxin and granted Brocade Guoxin regional general agency authority in Hunan and Hubei for the related products produced and developed by the company. this will help to strengthen the company's future market development and market influence in the central and western regions.

Health Information main business: general projects: engaged in technology development, technology transfer, technology consultation and technical services in the field of information technology and automation equipment; wholesale and retail of electronic products, network equipment and accessories, automation equipment, computers, software and auxiliary equipment; self-owned equipment leasing; computer software development; computer information system integration; type I medical device sales; category II medical device sales. (except for the projects that must be approved according to law, carry out business activities independently according to law on the strength of the business license) licensed projects: the third category of medical device business. (for projects that must be approved according to law, business activities can only be carried out with the approval of the relevant departments, and the specific business projects shall be subject to the approval documents or permits of the relevant departments.

The company's main income was 152 million yuan, up 20.74% from the same period last year, the company's main income was 152 million yuan, up 20.74% from the same period last year, the net profit was 51.7625 million yuan, up 21.4% from the same period last year, deducting 46.4118 million yuan from non-net profit, up 24.62% from the same period last year, and the debt ratio was 9.95%, investment income was 34300 yuan, financial expenses were-2.7325 million yuan, and gross profit margin was 59.65%, according to the report in 2021.